Literature DB >> 15078187

Nicotinic acetylcholine receptors as drug targets.

R C Hogg1, D Bertrand.   

Abstract

While it has long been documented that nicotine contained in tobacco leaves gives rise to major public health problems it has also been observed that this alkaloid can have beneficial effects. However, it is only with the identification of a family of genes coding for the neuronal nicotinic acetylcholine receptors and increased knowledge of their expression and function in the central nervous system that these receptors have received attention concerning their potential as drug targets. In light of the latest findings about nicotinic acetylcholine receptors and their involvement in disease states we review the possibility to design new drugs targeted to these ligand-gated channels. Beneficial and possible undesirable actions of agonists, antagonists and allosteric modulators are discussed and placed in perspective of our most recent knowledge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078187     DOI: 10.2174/1568007043482507

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  25 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

2.  Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.

Authors:  H Rollema; A Shrikhande; K M Ward; F D Tingley; J W Coe; B T O'Neill; E Tseng; E Q Wang; R J Mather; R S Hurst; K E Williams; M de Vries; T Cremers; S Bertrand; D Bertrand
Journal:  Br J Pharmacol       Date:  2010-03-22       Impact factor: 8.739

3.  Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach.

Authors:  Bogdan Iorga; Denyse Herlem; Elvina Barré; Catherine Guillou
Journal:  J Mol Model       Date:  2005-12-22       Impact factor: 1.810

4.  Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.

Authors:  Sheela K Chellappan; Yingxian Xiao; Werner Tueckmantel; Kenneth J Kellar; Alan P Kozikowski
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

5.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

6.  Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.

Authors:  Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

7.  Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors.

Authors:  Jeppe A Olsen; Philip K Ahring; Jette S Kastrup; Michael Gajhede; Thomas Balle
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

Review 8.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 9.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

10.  Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Authors:  Min Hu; Murali Gopalakrishnan; Jinhe Li
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.